이엔셀

이엔셀(456070)은 2018년에 설립된 세포·유전자 치료제 위탁개발생산(CDMO) 및 신약 개발 전문 기업입니다. 주요 사업은 다음과 같습니다:

- CDMO 서비스: 첨단 바이오의약품의 개발 및 위탁 생산.
- 신약 개발: 희귀 및 난치성 근육질환(샤르코-마리-투스병, 듀센 근디스트로피 등)을 대상으로 한 차세대 줄기세포 및 유전자 치료제 개발.

이엔셀은 코스닥 시장에 2024년 8월 상장했으며, 주요 파이프라인으로는 중간엽 줄기세포 치료제 ‘EN001’이 있습니다. 이 제품은 현재 임상 1b/2상을 진행 중입니다[1][6][7].

 금일 주가 상승 이유

2025년 2월 21일, 이엔셀의 주가는 전일 대비 19.34% 상승하며 21,600원에 거래되었습니다. 이는 다음과 같은 요인들로 분석됩니다:

1. 기관 및 개인 투자자 매수세: 

최근 기관과 개인 투자자들의 매수세가 이어지며 주가 상승을 견인했습니다. 반면 외국인은 일부 매도한 것으로 나타났습니다[3].
   
2. 거래량 증가: 

금일 거래량은 약 247만 주로, 전일 대비 크게 증가하며 시장의 관심이 집중되었습니다[3].

3. 기술적 반등: 

전날 소폭 하락 이후 다시 급등세를 보이며 기술적 반등 흐름을 이어갔습니다. 이는 최근 상승세와 맞물려 투자 심리를 자극한 것으로 보입니다[3].

4. 바이오 업종에 대한 긍정적 전망: 세포·유전자 치료제(CGT) 시장의 성장 가능성과 이엔셀의 CDMO 사업 확장 기대감이 주가 상승에 기여했습니다[5][6].

이엔셀은 바이오 업종 내에서도 희귀질환 신약 개발과 CDMO 사업에서 두각을 나타내며 투자자들의 지속적인 관심을 받고 있습니다.

Citations:
[1] https://www.eugenefn.com/common/files/amail/20240806_B_jongsun.park_2167.pdf
[2] https://www.saramin.co.kr/zf_user/company-info/view/csn/TUl0MFpZL1pCbFp4ckJHeDhCMVM1QT09/company_nm/%EC%9D%B4%EC%97%94%EC%85%80(%EC%A3%BC)
[3] https://www.cbci.co.kr/news/articleView.html?idxno=486243
[4] https://news.nate.com/view/20240902n02524
[5] http://www.dailyinvest.kr/news/articleView.html?idxno=62451
[6] https://www.sisajournal-e.com/news/articleView.html?idxno=405422
[7] https://m.thinkpool.com/compDiscuss/cont/1014110
[8] https://www.sedaily.com/NewsView/2DI9ROKMIJ
[9] https://pharm.edaily.co.kr/News/Read?newsId=01597366639122784
[10] https://www.newsis.com/view/NISX20240823_0002860603
[11] https://marvellab.maxnmarvel.com/company_report.php?ct_idx=1009&turn=2024-06-05
[12] https://comp.fnguide.com/SVO2/ASP/SVD_Main.asp?pGB=1&gicode=A456070&MenuYn=Y&ReportGB=D&NewMenuID=Y&stkGb=701
[13] https://comp.fnguide.com/svo2/fncompany.asp?gicode=A456070
[14] https://stock.pstatic.net/stock-research/company/31/20241010_company_501574000.pdf
[15] https://stockplus.com/m/stocks/KOREA-A456070
[16] https://comp.fnguide.com/SVO2/ASP/SVD_Main.asp?gicode=A456070
[17] https://www.valueline.co.kr/finance/summary/456070
[18] https://www.jobplanet.co.kr/companies/392898/landing/%EC%9D%B4%EC%97%94%EC%85%80
[19] https://finance.finup.co.kr/Stock/456070
[20] https://www.teamblind.com/kr/company/%EC%9D%B4%EC%97%94%EC%85%80
[21] http://www.encellinc.com
[22] https://stockplus.com/m/stocks/KOREA-A456070/analysis
[23] https://www.38.co.kr/html/fund/?o=v&no=2064
[24] https://biz.chosun.com/stock/c-biz_bot/2025/02/21/36ICDPJXAVU6WKAYFYWPM45KR4/
[25] https://m.thinkpool.com/compDiscuss/cont/1014299
[26] https://www.cbci.co.kr/news/articleView.html?idxno=486253
[27] https://pharm.edaily.co.kr/news/read?newsId=01836806639054232
[28] https://www.mk.co.kr/news/stock/11246498
[29] https://www.mk.co.kr/news/stock/11246522
[30] https://www.gukjenews.com/news/articleView.html?idxno=3207583
[31] https://www.youtube.com/watch?v=RVGLmpUZZOk
[32] https://www.youtube.com/watch?v=yJgxZhXpiTw
[33] https://www.38.co.kr/html/forum/board/?code=456070
[34] https://www.youtube.com/watch?v=6bGu-2tLV7o
[35] https://www.hankyung.com/reporter/2360
[36] https://career.rememberapp.co.kr/job/company/1583334
[37] https://thevc.kr/encell
[38] http://www.encellinc.com/kr/sub/company/overview.asp